Biotech

All Articles

Actinogen's cortisol blocker falls short stage 2 anxiety study

.Actinogen Medical's cortisol blocker has skipped the main endpoint of a stage 2 research in anxiety...

Bivictrix determines going personal only method to take ADC in to medical clinic

.Antibody-drug conjugates (ADCs) have gone to the center of several a billion-dollar biobuck licensi...

TPG leadings up funds to $580M for assets throughout lifestyle sciences

.Property supervisor TPG, which has actually supported biotechs such as Sionna Rehabs as well as San...

Merck quits phase 3 TIGIT trial in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT system has gone through one more problem. Months after shuttering a period 3...

After a hard year, Exscientia folds right into Recursion

.After a year described by pipeline hairstyles, the shift of its CEO and unemployments, Exscientia w...

Cullinan, after $25M bargain, restore bispecific to Port

.Cullinan Therapeutics was actually excited enough with Harbour BioMed's bispecific immune system re...

A closer look at Intense Biotech's Brutal 15

.In this particular full week's incident of "The Top Pipe," we are actually diving into Ferocious Bi...

Lilly faces period 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's party celebrating the approval of Alzheimer's...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings...

Lykos will definitely ask FDA to reevaluate its selection following rejection of MDMA therapy for post-traumatic stress disorder

.Observing a poor presenting for Lykos Therapeutics' MDMA candidate for trauma at a recent FDA consu...